Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2022

View Archived Issues

Targeting secretogranin III induces antiangiogenic effect during choroidal neovascularization

Dual Kv7 channel/TPSO receptor activator GRT-X shows promise in a refractory seizure model

Betta Pharmaceuticals discovers CD73 inhibitors

New MET/MERTK/TRYO3/AXL inhibitors identified at Aucentra Therapeutics

New IL-17RA antagonists presented by Hitgen

Shanghai Institute of Materia Medica patents glucose-lowering agents

Chengdu Fanxi Biopharma identifies PPAR-alpha and/or PPAR-delta agonists

New antipsychotic shows partial agonist activity at DRD2/3 and 5-HT1AR with little 5-HT2AR binding

STI-1558 strongly inhibits Omicron variant in cell-based assays

ATH-434 demonstrates efficacy in preclinical multiple system atrophy

Design of a next-generation cell-based therapy against diabetes

Improved retinal transplants ready for clinical trials

IDE-161 enters IND-enabling studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...